Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial.
Merck’s new antibody clesrovimab and other long-lasting shots promise to both expand and simplify care of newborns across the world to combat respiratory syncytial virus.
Big pharma and investors are piling into the precision radiation space as the next generation of increasingly potent targeted α-particle therapies promises to destroy cancerous cells with minimum damage to healthy tissues.
Startups targeting DNA repair seek to build on recent findings that neurodegeneration in Huntington’s disease is triggered only after CAG triplet repeats reach a critical threshold.
Genome sequencing in newborns is delivering insights into severe genetic diseases not afforded by traditional tests, but integrating genomics into newborn screening remains a logistics and cost challenge.
Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation of addiction-free pain drugs acting at NaV1.8 sodium channels.
Companies are striking unconventional benefit-sharing agreements with national governments to scour planet hotspots, gathering thousands of new DNA and protein sequences to develop into new, commercially useful molecules.
The first clinical results in patients with a genetic form of frontotemporal dementia (FTD) show that enhancing progranulin in the brain may halt disease progression. If successful, this potentially disease-modifying approach may uncover new avenues for treating other neurodegenerative diseases.
From corn to bananas, farmers stand to gain from cultivating edited crops that are resilient and sustainable, paired with precision insecticides and microbe engineering. But reaching those with the greatest need remains a challenge.
From mRNA drugs and the Achilles heel of obesity drugs, to single-cell biology and foundation models for drug discovery, these are some of the big stories most viewed by our readers.
